Antimicrobial activity of lff571 and three treatment agents against clostridium difficile isolates collected for a pan-european survey in 2008: Clinical and therapeutic implications

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1305-1311

  Debast, Sylvia B ^a   Bauer, Martijn P ^a   Sanders, Ingrid M J G ^a   Wilcox, Mark H ^b   Kuijper, Ed J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Fidaxomicin; Metronidazole; MICs; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; FIDAXOMICIN; LFF 571; METRONIDAZOLE; UNCLASSIFIED DRUG; VANCOMYCIN;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CAUSE OF DEATH; CLADISTICS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; EUROPE; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; RIBOTYPING;

FIDAXOMICIN; METRONIDAZOLE; MICS; VANCOMYCIN;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EUROPE; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; POLYMERASE CHAIN REACTION; RIBOTYPING; THIAZOLES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84882403677     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt013     Document Type: Article

References (54)

1. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
2. Kuijper EJ, Coignard B, Tü ll P. Emergence of Clostridium difficileassociated disease in North America and Europe. Clin Microbiol Infect 2006; 12: 2-18.
3. Goorhuis A, Van der Kooi T, Dekker FW et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007; 45: 695-703.
4. Kuijper EJ, Barbut F, Brazier JS et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe. Euro Surveill 2008; 13: pii=18942.
5. Goorhuis A, Bakker D, Corver et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47: 1162-70.
6. Hensgens MPM, Keessen EC, Squire MM et al. Clostridium difficile infection in the community: a zoonotic disease? Clin Microbiol Infect 2012; 18: 635-45.
7. Bauer MP, Notermans DW, van Benthem BHB et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73.
8. Songer JG, Trinh HT, Killgore GE et al. Clostridium difficile in retail meat products, USA 2007. Emerg Infect Dis 2009; 15: 819-12.
9. Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis 2011; 24: 370-6.
10. Bauer MP, Kuijper EJ, van Dissel JT et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-79.
11. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
12. Le F, Arora V, Sha DN et al. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy 2012; 32: 129-34.
13. Pepin J. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? Clin Infect Dis 2008; 46: 1493-8.
14. Al Nassir WN, Sethi AK, Nerandzic et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 56-62.
15. Kuijper EJ, Wilcox MH. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008; 47: 63-5.
16. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
17. Herpers BL, Vlaminckx B, Burkhardt O et al. Tigecycline for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48: 1732-5.
18. Rubin DT, Sohi S, Glathar M et al. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract 2011; 2011: 106978.
19. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-9.
20. Whitman CB, Czosnowski QA. Fidaxomicin for the treatment of Clostridium difficile infections. Ann Pharmacother 2012; 46: 219-28.
21. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
22. Tenover FC, Tickler IA, Persing DH. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother 2012; 56: 2929-32.
23. Brazier JS, Raybould R, Patel B et al. Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English hospitals, 2007-08. Euro Surveill 2008; 13: pii=19000.
24. Noren T, Alrikkson I, Akerlund T et al. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993- 2007 in Sweden. Clin Microbiol Infect 2010; 16: 1104-10.
25. Freeman J, Stott J, Baines SD et al. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005; 56: 988-9.
26. Barbut F, Decre D, Burghoffer B et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43: 2607-11.
27. Brazier JS, Fawley W, Freeman J et al. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48: 741-2.
28. Pelaez T, Alcala L, Alonso R et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46: 1647-50.
29. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
30. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-90.
31. Johnson S, Sanchez JL, Gerding D. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000; 31: 625-6.
32. LaMarche MJ, Leeds JA, Amaral A et al. Discovery of LFF571: an investigational agent for Clostridium difficile infection. J Med Chem 2012; 55: 2376-87.
33. Leeds JA, Sachdeva M, Mullin S et al. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother 2012; 56: 4463-5.
34. Trzasko A, Leeds JA, Praestgaard J et al. The efficacy of LFF571 in the hamster model of Clostridium difficile infection. Antimicrob Agents Chemother 2012; 56: 4459-62.
35. Baumann S, Schoof S, Bolten M et al. Molecular determinants of microbial resistance to thiopeptide antibiotics. J Am Chem Soc 2010; 132: 6973-81.
36. Bidet P, Lalande V, Salauze B et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000; 8: 2484-87.
37. Kato H, Kato N, Watanabe K et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 1998; 36: 2178-82.
38. Paltansing S, van den Berg RJ, Guseinova RA et al. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 2007; 13: 1058-64.
39. Stubbs S, Rupnik M, Gibert M et al. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186: 307-12.
40. Griffiths D, Fawley W, Kachrimanidou M et al. Multilocus sequence typing of Clostridium difficile. J Clin Microbiol 2010; 48: 770-8.
41. Knetsch W, Terveer EM, Lauber C et al. Comparative analysis of an expanded C. difficile reference strain collection reveals genetic diversity and evolution through six lineages. Infect Genet Evol 2012; 12: 1577-85.
42. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2005.
43. Barbut F, Mastrantonio P, Delmee M et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterization of the isolates. Clin Microbiol Infect 2007; 13: 1048-57.
44. Hecht DW, Galang MA, Sambol SP et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51: 2716-9.
45. Zaiβ NH, Witte W, Nü bel U. Fluoroquinolone resistance and Clostridium difficile, Germany. Emerg Infect Dis 2010; 16: 675-7.
46. Poilane I, Cruaud P, Torlotin JC et al. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin Microbiol Infect 2001; 6: 155-6.
47. Krook A, Jarnerot G, Danielsson D. The effect of metronidazole and sulfasalazine on Crohn's disease in relation to changes in the fecal flora. Scand J Gastroenterol 1981; 16: 569-75.
48. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-72.
49. Arabi Y, Dimock F, Burdon DW et al. Influence of neomycin and metronidazole on colonic microflora of volunteers. J Antimicrob Chemother 1979; 5: 531-7.
50. Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
51. Nagy E, Földes J. Inactivation of metronidazole by Enterococcus faecalis. J Antimicrob Chemother 1991; 27: 63-70.
52. Rafii F, Wynne R, Heinze TM et al. Mechanism of metronidazoleresistance by isolates of Enterococcus gallinarum and Enterococcus casseliflavus fromthe human intestinal tract. FEMS Microbiol Lett 2003; 225: 195-200.
53. Purdell J, Fawley W, Freeman J et al. Investigation of outcome in cases of Clostridiumdifficile infection due to isolates with reduced susceptibility to metronidazole. In: Abstracts of the Twenty-first European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, 2011. Abstract 0499. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
54. Freeman J, Fawley WN, Best E et al. Clustering of Clostridium difficile isolates with reduced susceptibility to metronidazole or vancomycin. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2011. Abstract C2-1807. American Society for Microbiology, Washington, DC, USA.